Diabetes insipidus (DI) is a disorder of inadequate urinary concentration leading to a polyuric state three litres in 24 hours) and is subdivided into either cranial or nephrogenic types. Cranial DI is due to decreased secretion of vasopressin from the pituitary gland. At least 80% of vasopressin-synthesising neurones must be destroyed before overt clinical features become manifest. In contrast, nephrogenic DI results from resistance of the distal renal tubules to the action of vasopressin 1 . In some cases it is possible to distinguish between these two types (by trial of desmopressin can also be used. After administration of desmopressin, patients with cranial DI will urine osmolality. In other words, the replacement of mopressin causes normal urinary concentration and resolution of the polyuria. In contrast, nephrogenic DI is characterised by a lack of response to desmopressin 2 .
There are many causes of nephrogenic DI, including congenital (a familial X-linked recessive disorder), metabolic (hypercalcaemia, hypokalaemia), vascular (sickle cell disease), chronic renal disease (pyelonephritis, sarcoidosis) and iatrogenic (lithium, demeclocycline) 2 . Lithium-induced DI is well documented (found in up to one third of patients on long-term lithium therapy) but it usually presents whilst the patient is still receiving the medication, often with preceding signs or symptoms. We wish to highlight a case in which the DI did not manifest until many days after the cessation of the patient's lithium therapy.
CASE REPORT
A 72-year-old woman presented to the accident and emergency department after involvement in a sisted of bipolar disorder, which was treated with
The accident resulted in severe bilateral below-knee degloving injuries with fractures of the ankle and due to severe blood loss from the degloving injuries and so was transferred to the operating theatre for wound debridement and haemostasis. Perioperatively she was transfused with 22 units of blood, four units of of colloid and 13 litres of crystalloid. Postoperatively she remained ventilated on the intensive care unit (ICU) where she developed disseminated intravascular coagulopathy, requiring further transfusions of tate. The patient's lithium was not administered during her stay on the ICU and subtherapeutic levels were measured on the 10th day after admission. Lithium-induced diabetes insipidus occurs in up to one third of patients on long-term therapy. It usually manifests during the treatment course, often with preceding signs or symptoms. We wish to highlight a case in which diabetes insipidus developed many days after cessation of long-term lithium therapy. We seek to explain this delayed onset by a discussion of the molecular and genetic changes underlying the pathogenesis of lithium-induced nephrogenic diabetes insipidus.
myoglobin test. On the fourth day the patient 160 mmol/l). Administration of 2 μg intravenous desmopressin (DDAVP) produced negligible reduction in the urine output and this therefore raised the possibility of a diagnosis of nephrogenic diabetes insipidus. At this point the urea was 6.6 mmol/l and creatinine was 118 μmol/l; serum calcium and potassium levels were normal. Supportive therapy was continued whilst the polyuria persisted and on the 10th day in the ICU a further 1 μg of DDAVP was given subcutaneously. Surprisingly, within an hour of the from greater than 200 ml/h to only 30-40 ml/h. of nephrogenic diabetes insipidus. The following morning the urine output once again increased to 400-450 ml/h and further doses of 2 μg intravenous DDAVP output settled to 40-60 ml/h. The hypernatraemia also settled slowly, falling to 145 mmol/l after two weeks.
the plasma and urine osmolalities were 311 and 447 mosmol/kg respectively. After 35 days on the ICU the patient was discharged to the ward and underwent further plastic surgery to her legs. She was seen several months later out of hospital and recovering well.
One third of patients on long-term lithium therapy develop DI. The mechanism behind the effect of lithium on renal tubules has been well researched and there is now a better understanding of the effects of lithium at genetic and molecular levels. Water reabsorption in the kidney takes place by a number of mechanisms, but one important structure that is involved is a vasopressin-regulated water channel known as aquaporin-2 (AQP2), which is found in the collecting ducts 3 . Vasopressin causes an increase in cytosolic 3:5-cyclic phosphatase which then acts as the second messenger to deliver AQP2 to the plasma membrane 3 . Water is then reabsorbed from the urine via these channels.
Studies in rats have demonstrated that treatment with high-dose lithium results in dramatically reduced whole kidney abundance of AQP2 4 . This
.
Furthermore, it is known that in some forms of DI there is also impaired delivery of the AQP2 channels to the apical plasma membrane 3 . Thus, the combination of decreased production of AQP2 and reduced delivery to its site of action results in impaired reabsorption of water from the urine, i.e. nephrogenic diabetes insipidus.
Lithium-induced nephrogenic DI is well documented. What was unusual about this case was the delay of onset of the DI following the cessation of the lithium therapy (on admission). Polyuria did not develop until four days after the lithium had been discontinued and it persisted until the 13th day of admission, well after a subtherapeutic plasma level of lithium had been demonstrated. The molecular changes underlying lithium-induced DI go some way AQP2 production and transport will take time to develop and thus their reversal will not be immediate on cessation of lithium. Studies have indeed shown after correction of the underlying condition 3 .
water channel has one more role to play. Further studies have shown that rats which were treated with lithium and developed DI and reduced AQP2 centrating abilities when treated with hydrochlororecovery in AQP2 abundance 6 are a useful tool in the management of diabetes insipidus.
In summary, this case highlights a delay in the development of diabetes insipidus in a patient who had been on prolonged lithium therapy. Whilst diabetes insipidus is a not uncommon complication of lithium, this case was unusual as the polyuria developed many days after the cessation of the patient's usual medication, without any preceding signs or a more detailed discussion of the molecular and genetic changes underlying lithium-induced diabetes insipidus. An understanding of these changes also diuretics in the treatment of diabetes insipidus. Whilst molecular genetics sometimes seems far removed from the hands-on management of a patient in ledge of the former can have a direct impact on the latter.
